机构：交通银行 Expect robust FY17 results; strong catalyst lies ahead    Expect strong FY17: We are optimistic on Sino Biopharm’s (SBP) FY17 financial performance, expecting 10% sales growth and 30% earnings growth (19% YoY on adj... 网页链接